Bayer Pharmaceutical posts 8th straight year of growth in AsPac

MANILA, Philippines — Bayer’s Pharmaceutical Division marked its eighth consecutive year of growth in Asia-Pacific in 2018, ranking anew as one of the fastest growing among top multinational pharmaceutical companies in the region by global health intelligence agency IQVIA.

In 2018, the region’s sales grew by 7.3 percent to over €5.2 billion, with many of the region’s markets delivering strong growth rates including Australia, South Korea, Taiwan, China, Philippines and Indonesia.

The region contributed more than 30 percent to the division’s global sales and continued to be the fastest growing reporting region for Bayer’s pharmaceutical business.

 “Our strong performance year after year speaks to the strong demand for our innovative medicines as they deliver significant benefits to patients battling serious diseases such as cardiovascular diseases, cancer, and eye diseases related to aging and diabetes. We will continue to bring new and better treatments to patients in the region and build more collaboration with external partners here,” Claus Zieler, SVP and head of commercial operations of Bayer Pharmaceuticals Division Asia Pacific, said.

Bayer’s key products, i.e. oral anticoagulant medicine, eye medicine, and oral cancer treatment, continued to be well received by doctors and patients in Asia-Pacific. By end of 2018, nearly 48 million packs of oral anticoagulant medicine have been delivered to patients in Asia-Pacific for blood clot prevention and treatment in several indications across the venous and arterial thromboembolic (VAT) space and about 3.5 million doses of eye medicine have been administered to patients in Asia-Pacific for treatment of several retinal disorders including wet age-related macular degeneration and diabetic macular edema.

As for oral cancer treatment, nearly 1.4 million packs have been delivered to patients in Asia-Pacific for treatment of late-stage liver cancer, advanced kidney cancer and differentiated thyroid cancer from 2010 to 2018.